- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Celsion Corp
+ Add to WatchlistCLSN:US
1.0400 USD 0.0500 5.05%
Share
As of 17:20:00 ET on 05/24/2013.
More on CLSN
News for Celsion Corp (CLSN)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Largest Nasdaq Short Interest Changes as of Feb. 28
- Largest Nasdaq Short Interest Changes as of Jan. 31
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Celsion Falls Most Ever After Liver Cancer Drug Fails
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Celsion Announces Issuance of Additional Patents Covering ThermoDox® Technologies Published May 22, 2013
- Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) Published May 17, 2013
- Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update Published May 09, 2013
- Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology Published May 01, 2013
- Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013 Published May 01, 2013
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- MS Patients Choose Death Risk With Potent Drug Treatment
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page